These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 32087612)

  • 1. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
    Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
    Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis.
    Whittle S; Venkatramani R; Schönstein A; Pack SD; Alaggio R; Vokuhl C; Rudzinski ER; Wulf AL; Zin A; Gruver JR; Arnold MA; Merks JHM; Hettmer S; Koscielniak E; Barr FG; Hawkins DS; Bisogno G; Sparber-Sauer M
    Eur J Cancer; 2022 Jun; 168():56-64. PubMed ID: 35452896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
    Alaggio R; Zhang L; Sung YS; Huang SC; Chen CL; Bisogno G; Zin A; Agaram NP; LaQuaglia MP; Wexler LH; Antonescu CR
    Am J Surg Pathol; 2016 Feb; 40(2):224-35. PubMed ID: 26501226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.
    Walther C; Mayrhofer M; Nilsson J; Hofvander J; Jonson T; Mandahl N; Øra I; Gisselsson D; Mertens F
    Genes Chromosomes Cancer; 2016 Jan; 55(1):3-15. PubMed ID: 26482321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR1 fusions as a novel molecular driver in rhabdomyosarcoma.
    de Traux De Wardin H; Cyrta J; Dermawan JK; Guillemot D; Orbach D; Aerts I; Pierron G; Antonescu CR
    Genes Chromosomes Cancer; 2024 Apr; 63(4):e23232. PubMed ID: 38607246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histology and fusion status in rhabdomyosarcoma.
    Rudzinski ER
    Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma.
    Karanian M; Pissaloux D; Gomez-Brouchet A; Chevenet C; Le Loarer F; Fernandez C; Minard V; Corradini N; Castex MP; Duc-Gallet A; Blay JY; Tirode F
    Am J Surg Pathol; 2020 May; 44(5):607-616. PubMed ID: 32187044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 12. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
    Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation profiling reveals novel molecular classes of rhabdomyosarcoma.
    Clay MR; Patel A; Tran Q; Hedges DJ; Chang TC; Stewart E; Charville G; Cline C; Dyer MA; Orr BA
    Sci Rep; 2021 Nov; 11(1):22213. PubMed ID: 34782706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
    Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
    Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
    Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
    Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm.
    Giannikopoulos P; Parham DM
    Pediatr Dev Pathol; 2021; 24(5):395-404. PubMed ID: 34107813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
    Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
    Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.